Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.9293
-0.0404 (-4.17%)
Sep 4, 2025, 4:00 PM - Market closed
Scienture Holdings Revenue
Scienture Holdings had revenue of $128.20K in the twelve months ending June 30, 2025, down -76.24% year-over-year. In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%.
Revenue (ttm)
$128.20K
Revenue Growth
-76.24%
P/S Ratio
62.96
Revenue / Employee
$6,747
Employees
19
Market Cap
17.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
| Dec 31, 2022 | 300.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 21 days ago - Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 22 days ago - SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. - GlobeNewsWire
- 6 weeks ago - Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding - GlobeNewsWire
- 7 weeks ago - Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Scienture Holdings Announces Cancelation of ELOC - GlobeNewsWire
- 3 months ago - Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value - Accesswire
- 3 months ago - SCIENTURE Announces Executive Leadership Transition - GlobeNewsWire
- 3 months ago - SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - GlobeNewsWire